Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) + Placebo to match aficamten
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Trial Timeline
Feb 1, 2022 โ Dec 18, 2023
NCT ID
NCT05186818About Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) + Placebo to match aficamten
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) + Placebo to match aficamten is a phase 3 stage product being developed by Cytokinetics for Obstructive Hypertrophic Cardiomyopathy (oHCM). The current trial status is completed. This product is registered under clinical trial identifier NCT05186818. Target conditions include Obstructive Hypertrophic Cardiomyopathy (oHCM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05186818 | Phase 3 | Completed |
Competing Products
20 competing products in Obstructive Hypertrophic Cardiomyopathy (oHCM)